AUTHORS
Amandeep Salhotra, MD, Iskra Pusic, MD MSCI2, Sally Arai, MD3, Annie Im, MD4, Mi Kwon , MD, PhD5, Britnie Thomas, PhD6, Valkal Bhatt, PharmD7, Zhenyi Xue, PhD8, Daniel Wolff, MD9
AFFILIATIONS
1 City of Hope National Medical Center, Duarte, California, United States
2 Washington University School of Medicine, Saint Louis, Missouri, United States
3 Stanford Health Care – Stanford Hospital, Stanford, California, United States
4 Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
5 General University Hospital Gregorio Marañón, Institute of Health Research, Madrid, Spain
6 Incyte Corporation, Wilmington, Delaware, United States
7 Incyte Corporation, Wilmington, Delaware, United States
8 Incyte Corporation, Wilmington, Delaware, United States
9 Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany
ABSTRACT
Introduction: Among patients (pts) who undergo allogeneic hematopoietic stem cell transplantation, chronic graft-versus-host disease (cGVHD) is a major cause of morbidity and mortality. In the pivotal AGAVE-201 trial (NCT04710576), the efficacy and safety of axatilimab (AXA), a high-affinity monoclonal antibody targeting colony-stimulating factor 1 receptor (CSF-1R), was evaluated for cGVHD; AXA 0.3 mg/kg every 2 weeks (Q2W) had the highest overall response rate in the first 6 cycles of 73.8% and was generally well tolerated.
Aims: To report long-term efficacy and safety with AXA in AGAVE-201.
Methods: Pts aged ≥2 years with cGVHD after ≥2 prior lines of systemic therapy were randomized 1:1:1 to intravenous AXA 0.3 mg/kg Q2W, 1 mg/kg Q2W, or 3 mg/kg every 4 weeks (Q4W). Pts could continue to receive concomitant corticosteroids (CS), mTOR inhibitors, and calcineurin inhibitors (CNIs). Overall and organ-specific responses were assessed per NIH 2014 criteria; cGVHD symptoms were assessed with the modified Lee Symptom Scale (mLSS). Pts who reported clinically meaningful symptom improvement and were deriving clinical benefit could continue AXA treatment.
Results: Among 241 pts enrolled, 239 received AXA (0.3 mg/kg Q2W, n=79; 1 mg/kg Q2W, n=81; 3 mg/kg Q4W, n=79). At baseline, median (range) age was 53 (7–81) years, 151 pts (62.7%) were male, 192 (79.7%) had severe cGVHD, 130 (53.9%) had ≥4 organs involved, and 108 (44.8%) had lung involvement. A total of 179 (74.3%), 75 (31.1%), and 56 (23.2%) pts had prior treatment with ruxolitinib, ibrutinib, and belumosudil, respectively. As of March 30, 2025, 206 pts discontinued or completed treatment and 33 pts were still on treatment. The most common reasons for treatment discontinuation were progressive disease (24.9%), adverse events (22.8%), and withdrawal of consent (13.7%). Among pts that received AXA 0.3 mg/kg Q2W, the median (range) duration of treatment was 11 (1–40) months, with 35 pts (44.3%) receiving AXA for ≥15 months. Organ-specific response rates in the AXA 0.3 mg/kg Q2W cohort were similar to the primary analysis, demonstrating responses (complete and partial) in all involved organs. The median (IQR) best change in mLSS was −9.3 (−15.2 to −2.5) points in the 0.3 mg/kg Q2W cohort; median (IQR) duration of ≥7-point mLSS improvement was 5 (2–8) cycles, with a maximum duration of 18 cycles. In the 0.3 mg/kg Q2W cohort, the 12-month rate (95% CI) of failure-free survival (time from randomization to addition of another systemic cGVHD therapy, relapse of underlying malignancy, or death) was 48.4% (36.9%–59.0%). With a median follow-up of 14.7 months in responders, the 12-month probability of response maintenance (95% CI) was 0.6 (0.5–0.7). Among 59 responders, median (95% CI) duration of response (DOR; time from first response to start of another systemic treatment or death, whichever is earlier) was 22.3 (10.1–30.4) months; the top quartile of responders had a DOR of 42.5 (95% CI, 28.8–not estimable) months. Among 56 pts in the 0.3 mg/kg Q2W cohort who received CS at baseline, 14 (25.0%) completely tapered off CS in ≤24 cycles. Among 17 pts in the 0.3 mg/kg Q2W cohort who received CNIs at baseline, 5 (29.4%) tapered off CNIs in ≤24 cycles. Outcomes across all doses were similar to those observed in the 0.3 mg/kg Q2W cohort. Treatment-emergent adverse events (TEAEs) were consistent with the primary analysis. In the 0.3 mg/kg cohort, fatigue (30.4%) was the only TEAE that occurred in ≥25% of pts. The most common TEAEs across all doses were increased lab parameters (creatine phosphokinase [38.9%], aspartate aminotransferase [38.1%], lipase [29.7%], alanine aminotransferase [26.8%], and lactate dehydrogenase [26.4%]) as well as fatigue (26.8%). A total of 15 pts (19.0%) in the 0.3 mg/kg Q2W cohort and 85 pts (35.6%) across all doses had ≥1 treatment-related grade ≥3 TEAE.
Conclusion: In the primary analysis of AGAVE-201, AXA 0.3 mg/kg Q2W was associated with clinical responses in all involved organs and a tolerable safety profile. After long-term treatment, organ-specific responses were similar to the primary analysis, but further analyses of the dynamics of organ-specific responses over time are warranted. With additional follow-up, overall clinical responses and symptom improvements were durable. At the data cutoff, ~25% of responders maintained response for ≥42 months. Overall, long-term treatment with AXA remained well tolerated and demonstrated prolonged clinical benefit.
DISCLOSURES
Amandeep Salhotra, MD: Sobi - Research Funding; Incyte - Research Funding; Rigel - Research Funding; Bristol-Myers Squibb - Research Funding; OrcaBio - Research Funding; Jazz Pharma - Research Funding; Pierview - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)